Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 4
1967 8
1968 10
1969 7
1970 14
1971 12
1972 14
1973 20
1974 21
1975 12
1976 8
1977 10
1978 8
1979 9
1980 4
1981 9
1982 14
1983 12
1984 15
1985 17
1986 23
1987 30
1988 30
1989 37
1990 70
1991 57
1992 61
1993 60
1994 58
1995 73
1996 56
1997 84
1998 69
1999 82
2000 79
2001 78
2002 108
2003 145
2004 137
2005 134
2006 151
2007 143
2008 160
2009 199
2010 204
2011 217
2012 217
2013 191
2014 151
2015 154
2016 142
2017 135
2018 134
2019 136
2020 107
2021 108
2022 149
2023 137
2024 103

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,230 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J; NefIgArd trial investigators. Lafayette R, et al. Lancet. 2023 Sep 9;402(10405):859-870. doi: 10.1016/S0140-6736(23)01554-4. Epub 2023 Aug 14. Lancet. 2023. PMID: 37591292 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Endothelin Receptor Antagonists in Kidney Disease.
Martínez-Díaz I, Martos N, Llorens-Cebrià C, Álvarez FJ, Bedard PW, Vergara A, Jacobs-Cachá C, Soler MJ. Martínez-Díaz I, et al. Int J Mol Sci. 2023 Feb 8;24(4):3427. doi: 10.3390/ijms24043427. Int J Mol Sci. 2023. PMID: 36834836 Free PMC article. Review.
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.
Mosenzon O, Wiviott SD, Heerspink HJL, Dwyer JP, Cahn A, Goodrich EL, Rozenberg A, Schechter M, Yanuv I, Murphy SA, Zelniker TA, Gause-Nilsson IAM, Langkilde AM, Fredriksson M, Johansson PA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Raz I. Mosenzon O, et al. Diabetes Care. 2021 Aug;44(8):1805-1815. doi: 10.2337/dc21-0076. Epub 2021 Jul 7. Diabetes Care. 2021. PMID: 34233928 Free PMC article.
Isolated asymptomatic proteinuria.
Srivastava RN. Srivastava RN. Indian J Pediatr. 2002 Dec;69(12):1055-8. doi: 10.1007/BF02724387. Indian J Pediatr. 2002. PMID: 12557959 Review.
Diabetic Nephropathy: From Pathophysiology to Treatment.
Shen Z, Fang Y, Xing T, Wang F. Shen Z, et al. J Diabetes Res. 2017;2017:2379432. doi: 10.1155/2017/2379432. Epub 2017 Oct 23. J Diabetes Res. 2017. PMID: 29201920 Free PMC article. No abstract available.
Non-immunosuppressive treatment for IgA nephropathy.
Tunnicliffe DJ, Reid S, Craig JC, Samuels JA, Molony DA, Strippoli GF. Tunnicliffe DJ, et al. Cochrane Database Syst Rev. 2024 Feb 1;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3. Cochrane Database Syst Rev. 2024. PMID: 38299639
4,230 results